Creative Planning’s BioXcel Therapeutics BTAI Stock Holding History

Creative Planning’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-827	Closed	-$37.3K	–	3084
2024 Q1	$37.3K	Sell	827 -437	-35%	-$20.8K	﹤0.01%	2804
2023 Q4	$59.7K	Sell	1,264 -63	-5%	-$3.5K	﹤0.01%	2631
2023 Q3	$53.7K	Buy	+1,327	New	+$134K	﹤0.01%	2475
2020 Q4	–	Sell	-406	Closed	-$282K	–	2355
2020 Q3	$282K	Buy	+406	New	+$305K	﹤0.01%	1453
2020 Q2	–	Sell	-682	Closed	-$244K	–	2029
2020 Q1	$244K	Sell	682 -246	-27%	-$88.4K	﹤0.01%	1278
2019 Q4	$217K	Buy	+928	New	+$93.3K	﹤0.01%	1583
2019 Q3	–	Sell	-1,000	Closed	-$175K	–	2007
2019 Q2	$175K	Sell	1,000 -909	-48%	-$154K	﹤0.01%	1656
2019 Q1	$302K	Buy	+1,909	New	+$235K	﹤0.01%	1323
2018 Q4	–	Sell	-834	Closed	-$102K	–	1965
2018 Q3	$102K	Buy	+834	New	+$124K	﹤0.01%	1784

Other funds holding BTAI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Creative Planning's BTAI Position: Q2 2024 in Review

Creative Planning sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 827 shares — an estimated $37.3K sold.

Creative Planning first reported a position in BTAI in Q3 2018 and held it in 9 quarters. The position peaked at $302K in Q1 2019. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

Creative Planning reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
Creative Planning sold 827 BioXcel Therapeutics shares in Q2 2024, an estimated $37.3K.
Creative Planning first reported a position in BioXcel Therapeutics in Q3 2018 and held it in 9 quarters.
Creative Planning's BioXcel Therapeutics position peaked at $302K in Q1 2019.
74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Creative Planning's 13F filing for Q2 2024, filed 15 Aug 2024.